secwatch.observer — SEC 8-K summary
======================================

Issuer:     Incannex Healthcare Inc. (IXHL)
CIK:        0001873875
Form:       8-K
Filed at:   2025-08-08T23:59:59+00:00
Accession:  0001213900-25-073321
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incannex reports positive Phase 2 data for IHL-42X in obstructive sleep apnoea; AHI reductions up to 83%
--------------------------------------------------------------------------------

- Low- and high-dose IHL-42X achieved statistically significant reduction in AHI vs placebo (p<0.05); max AHI reduction 83% in high-dose group.
- 41.2% of high-dose group achieved >30% AHI reduction; 14.7% had >50% reduction; no reduction in REM sleep.
- 89.5% of patients reporting improvement described change as meaningful; benefits included improved sleep quality and reduced daytime fatigue.
- No serious adverse events; treatment-emergent adverse effects infrequent, mild/moderate; drug well tolerated.
- CEO notes share price volatility, states company is well-capitalized and considering strategic levers including anti-dilution measures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873875/000121390025073321/0001213900-25-073321-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873875/000121390025073321/ea0252400-8k_incannex.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-073321

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer